Phase 1 Clinical Study of Mgta-145 in Combination with Plerixafor Shows Rapid Single-Day Mobilization and Collection of CD34+ HSCs without G-CSF

G-CSF mobilization of hematopoietic stem cells (HSCs) requires 4-7 days of injections that provide unreliable collections. G-CSF is associated with significant side effects and potential for fatal complications in some patient populations (e.g. sickle cell disease, multiple sclerosis). MGTA-145 is an analog of the chemokine GRO β that activates CXCR2 and with plerixafor rapidly mobilizes HSCs in mice and non-human primates. The combination promises to be a same-day mobilization regimen that does not require G-CSF.

Source: Biology of Blood and Marrow Transplantation - January 24, 2020 Category: Hematology Authors: John F. DiPersio, Steven M. Devine, Jonathan Hoggatt, David Scadden, Haley Howell, Veit Schmelmer, Jason Neale, Anthony E. Boitano, Michael P. Cooke, Kevin A. Goncalves, Glen D. Raffel, William Savage, Patrick C. Falahee, Dwight M. Morrow, John C. Davis Tags: 73 Source Type: research